Alteplase: 5 agencies, 2003–2018
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused alteplase: all 9 decisive outcomes across 5 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 15.2 years separate the first record, 2 Jul 2003 at HAS (France), from the most recent, 12 Sep 2018 at CONITEC (Brazil).
SMC (Scotland) changed its position: restricted on 8 Mar 2004, recommended by 11 Jun 2012.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden) among them — hold no record for alteplase at all.
Nothing has been added since 2018; on this evidence the file is dormant.
6 distinct indication wordings are recorded for alteplase by the agencies that label one in English (AWMSG, NICE and SMC).
HAS (France) was first to assess alteplase, on 2 Jul 2003; CONITEC (Brazil) did not open a file until 12 Sep 2018 — an unusually long tail of 15.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 4 of 10 dated records fall in 2012 alone.
3 of the 5 agencies here assessed alteplase more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed alteplase.
The full ledger for alteplase reads 7 recommended, 2 restricted and 1 not assessed.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 12 Sep 2018 | Tratamento da embolia pulmonar aguda | incorporated into SUS | source |
| NICE (England) | 26 Sep 2012 | NICE TA264 | recommended | source |
| HAS (France) | 4 Jul 2012 | Indication extension | SMR substantial · ASMR III | source |
| SMC (Scotland) | 8 Aug 2011 | For thrombolytic treatment of occluded central venous access devices (CVAD). | accepted (restricted) | source |
| AWMSG (Wales) | 27 Apr 2010 | Fibrinolytic treatment of acute ischaemic stroke. Treatment must be started as early as possible within 4.5 hours after … | outside AWMSG criteria | source |
5 further decisions for alteplase, across 3 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- rivaroxaban — same ATC class B01A — Antithrombotics
- apixaban — same ATC class B01A — Antithrombotics
- enoxaparin — same ATC class B01A — Antithrombotics
- dabigatran — same ATC class B01A — Antithrombotics
- fondaparinux — same ATC class B01A — Antithrombotics
- ticagrelor — same ATC class B01A — Antithrombotics
Coverage: 10 decisions for alteplase from 5 agencies, 2003 to 2018. Data to 7 Sep 2026. ATC class B01A — Antithrombotics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.